查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024974

病毒載體生產市場規模、佔有率、趨勢和預測：按類型、疾病、應用、最終用戶和地區分類，2026-2034年

Viral Vector Manufacturing Market Size, Share, Trends and Forecast by Type, Disease, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年全球病毒載體生產市場規模為17.863億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到95.499億美元，2026年至2034年的複合年成長率（CAGR）為19.86%。目前，北美市場佔據主導地位，預計到2025年將佔據超過49.3%的市場。遺傳疾病盛行率的上升、基因療法的擴展、先進的生物技術基礎設施、不斷擴大的臨床試驗、強力的政府資助、強勁的研發投入以及主要廠商的存在，都是推動北美病毒載體生產市場成長的因素。

全球病毒載體生產市場正經歷顯著成長，其主要驅動力是遺傳性疾病和感染疾病的日益普遍，以及基因和細胞療法的進步。病毒載體在罕見疾病、癌症和神經系統疾病創新治療方法開發中的廣泛應用，是推動市場需求的主要因素。基因療法臨床試驗的擴展以及政府對生物技術和製藥研發投入的增加，進一步促進了市場成長。此外，可擴展生產技術的開發和生產流程的改進提高了病毒載體生產的效率和成本效益。製藥公司與研究機構之間合作的加強也加速了新治療方法的研發，進一步推動了病毒載體生產市場的成長。

美國已成為領先的市場之一，佔了91.90%的市場佔有率，這主要得益於幾個關鍵因素。其中一個關鍵促進因素是遺傳性疾病和癌症的日益普遍，這增加了對使用病毒載體的基因和細胞療法的需求。政府對生物技術的大量投資以及美國境內眾多合約研發生產機構（CDMO）的存在進一步推動了這一成長。此外，可擴展生產技術的進步提高了生產效率，以滿足日益成長的病毒載體治療需求。基因療法研發管線的擴展和臨床試驗的增加也促進了市場成長，使美國成為病毒載體生產的重要中心。

病毒載體生產市場的發展趨勢：

市場成長與投資

截至2024年3月18日，美國食品藥物管理局（FDA）已核准36種基因療法，另有500多種正在研發中。 FDA預測，到2025年，每年將核准約10至20種基因療法產品。這一成長主要得益於生物技術投資的增加以及基因治療領域新技術的開發。 FDA積極監管基因療法，使得部分治療方法得以加快核准流程並獲得事先核准。預計的年度核准數量表明，人們對基因療法的安全性和有效性越來越有信心。已獲核准的基因療法數量以及強大的研發管線表明，基因療法市場充滿活力，具有巨大的成長潛力。預計這一趨勢將持續下去，市場擴張主要得益於FDA對創新治療方法的承諾。為了滿足不斷成長的需求，製藥公司正在大力投資病毒載體的生產，因為高品質病毒載體的持續供應對於確保基因療法的成功至關重要。克服擴大生產規模的挑戰需要FDA的支持以及產業對生產基礎設施的投資。這些努力旨在確保更多患者能夠從基因治療中受益。

技術進步和工藝最佳化

病毒載體生產技術的進步，例如細胞株的開發和生產流程的改進，正在推動市場成長。穩定的包裝細胞株提高了病毒載體的生產效率，從而促進了市場成長。例如，三星生物製劑採用的HEK293細胞株技術在2022年將病毒載體產量提高了25%。隨著自動化和人工智慧技術融入生產流程，這一成長速度將進一步加快，因為這將降低成本並簡化規模化生產。這對於滿足基因治療領域對臨床級病毒載體日益成長的需求至關重要。

監管和生產方面的挑戰

儘管病毒載體生產市場前景廣闊，但仍面臨許多挑戰，其中許多挑戰與監管和規模化生產的困難有關。根據2023年的一篇報導報導，基於病毒載體的治療方法的核准流程日益漫長，有時甚至需要三到五年。此外，如何在確保品管和最大限度減少生產過程中污染物暴露的同時核准，也是一項重大挑戰。為此，包括FDA和EMA在內的監管機構正與產業相關人員合作，制定更清晰的病毒載體生產指南​​。不斷變化的監管環境可能會影響生產策略，進而可能延緩產品上市時間，最終影響整個產業的成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球病毒載體生產市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 腺病毒載體
  • 腺結合病毒載體
  • 慢病毒載體
  • 逆轉錄病毒載體
  • 其他

第7章 市場區隔：依疾病分類

  • 癌症
  • 遺傳性疾病
  • 感染疾病
  • 其他

第8章 市場區隔：依應用領域分類

  • 基因治療
  • 疫苗學

第9章 市場區隔：依最終用戶分類

  • 製藥和生物製藥公司
  • 研究機構

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Aldevron LLC
    • Catalent, Inc
    • Charles River Laboratories International Inc.
    • Cytiva（Danaher Corporation）
    • F. Hoffmann-La Roche Ltd
    • FUJIFILM Diosynth Biotechnologies
    • Genezen
    • Kaneka Corporation
    • Lonza
    • Merck KGaA
    • Oxford Biomedica PLC
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A5016

The global viral vector manufacturing market size was valued at USD 1,786.3 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 9,549.9 Million by 2034, exhibiting a CAGR of 19.86% from 2026-2034. North America currently dominates the market, holding a market share of over 49.3% in 2025. The rising prevalence of genetic disorders, increasing adoption of gene therapies, advanced biotechnology infrastructure, expanding clinical trials, strong government funding, robust R&D investments, and the presence of leading pharmaceutical companies drive the viral vector manufacturing market in North America.

The global viral vector manufacturing market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and infectious diseases, coupled with advancements in gene and cell therapy. The growing adoption of viral vectors in the development of innovative therapies for rare diseases, cancer, and neurological disorders is a key factor boosting demand. Expanding clinical trials for gene therapies and rising government investments in biotechnology and pharmaceutical research are further supporting market expansion. Moreover, the development of scalable manufacturing technologies and improved production processes has boosted the efficiency and cost-effectiveness of viral vector production. Increasing collaborations between pharmaceutical companies and research institutions are also accelerating the development of novel therapies, further propelling the growth of the viral vector manufacturing market.

The United States is emerging as one of the key markets with 91.90% of the total market share, propelled by several key factors. A significant driver is the increasing prevalence of genetic disorders and cancers, which has intensified the demand for gene and cell therapies utilizing viral vectors. This growth is further supported by substantial government investments in biotechnology and the presence of numerous contract development and manufacturing organizations (CDMOs) in the country. Additionally, advancements in scalable manufacturing technologies have enhanced production efficiency, meeting the rising demand for viral vectors in therapeutic applications. The expanding pipeline of gene therapies and increasing clinical trials are also contributing to the market's expansion, positioning the U.S. as a leading hub for viral vector manufacturing.

VIRAL VECTOR MANUFACTURING MARKET TRENDS:

Market Growth and Investment

As of March 18, 2024, the FDA has approved 36 gene therapies. There are more than 500 in development. The agency predicts that, by 2025, it will approve around 10 to 20 products every year in gene therapy. The increase is fueled by a boost in biotechnology investment and new technologies being developed in the gene therapy arena. Proactivity by the FDA in regulating gene therapy has allowed a few of these treatment solutions to be fast-tracked and approved rapidly. The expected approvals annually represent the growing trust built for the safety and efficacy profiles of gene therapies. The actual number of approved gene therapies and the robust pipeline depict an active market poised for significant growth. This trend is set to continue; however, market expansion will significantly be driven by the commitment by the FDA toward innovative therapies. As a response to this increase, pharmaceutical firms are investing extensively in viral vector manufacturing to answer the growing demands of gene therapy. This is because a sustained supply of good quality viral vectors is essential in guaranteeing successful gene therapies. The FDA support and the industry investment in manufacturing infrastructure are critical to overcome the challenges of scaling up production. These efforts are meant to ensure that the benefits of gene therapies are accessible to a broader patient population.

Technological Advancements and Process Optimization

The growth in the market is driven by the technological advancement in viral vector manufacturing, such as cell line development and improvement in production processes. The stable packaging cell lines increase the efficiency of viral vector production, thereby fueling the growth of the market. For instance, the HEK293 cell line technology adopted by Samsung Biologics increased viral vector yield by 25% in 2022. This will be further facilitated by the automation and AI that is being incorporated into manufacturing processes. It lowers costs and simplifies scaling. This is necessary to meet the increased demand for clinical-grade viral vectors for gene therapies.

Regulatory and Manufacturing Challenges

Despite these development prospects, this viral vector manufacturing market is struggling with several issues, most of which involve regulating and the difficulties of scaling up production. According to a 2023 article, approval times for viral vector-based therapies are becoming increasingly lengthy, with approval processes sometimes taking as long as 3-5 years. Additionally, scaling up while ensuring quality control and minimizing contaminant exposures during manufacturing is one area of major concern. In response, the FDA and EMA, among other regulatory bodies, are engaging with industry stakeholders to establish clearer guidelines for the manufacturing of viral vectors. The evolving regulatory landscape will influence production strategies and could slow the time to market, thus affecting the overall growth of the industry.

VIRAL VECTOR MANUFACTURING INDUSTRY SEGMENTATION:

Analysis by Type:

  • Adenoviral Vectors
  • Adeno-associated Viral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Others

In 2025, Adeno-associated viral (AAV) vectors emerge as the largest segment in the viral vector manufacturing market, driven by their versatility and safety profile. AAV vectors are frequently utilized in gene therapy due to their minimal immune response and their effectiveness in delivering therapeutic genes to specific target cells with precision. Their significant role in treating genetic disorders, such as spinal muscular atrophy (SMA) and inherited retinal diseases, has propelled their demand. The ongoing advancements in AAV vector engineering have further enhanced their efficiency, scalability, and therapeutic potential. Additionally, the increasing number of FDA-approved AAV-based therapies and the growing pipeline of clinical trials utilizing AAV vectors reinforce their dominance, making them a crucial component of the expanding gene therapy landscape.

Analysis by Disease:

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

In 2025, cancer emerged as the leading application segment in the viral vector manufacturing market, accounting for approximately 37.6% of the market share. The dominance of this segment is attributed to the growing adoption of viral vectors in gene therapies and oncolytic virotherapy for treating various types of cancer. Advances in immunotherapy, such as CAR-T cell therapies, which rely on viral vectors for genetic modifications, have further driven this growth. The growing global prevalence of cancer, along with increased investments in oncology research and clinical trials, has driven the demand for innovative treatment solutions. Furthermore, the approval of viral vector-based therapies for specific cancers highlights their efficacy, solidifying their role in transforming cancer treatment strategies globally.

Analysis by Application:

  • Gene Therapy
  • Vaccinology

In 2025, gene therapy dominated the viral vector manufacturing market, accounting for approximately 56.9% of the market share. This leadership is driven by the growing adoption of gene therapies to treat genetic disorders, cancers, and rare diseases. Viral vectors, especially adeno-associated viruses (AAV) and lentiviruses, play a crucial role in delivering therapeutic genes to target cells with accuracy and efficiency. The expanding pipeline of gene therapy candidates and increasing regulatory approvals have significantly boosted demand. Notable advancements in viral vector engineering and scalable manufacturing technologies further support this segment's growth. Additionally, rising investments from pharmaceutical companies and government initiatives aimed at advancing gene therapy research contribute to its prominence, positioning it as a transformative force in modern medicine.

Analysis by End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Pharmaceutical and biopharmaceutical companies are the primary end-users in the viral vector manufacturing market. These companies drive demand due to their extensive use of viral vectors in gene and cell therapy development, clinical trials, and commercial-scale manufacturing. Rising investments in personalized medicine and innovative therapies further strengthen this segment's dominance.

Research institutes play a crucial role in the viral vector manufacturing market by fostering innovation and advancing preclinical studies. These institutes focus on developing novel therapies for genetic disorders, cancer, and rare diseases. Collaborations with pharmaceutical companies and increased government funding for biotechnology research further enhance their contribution to market growth.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The market share in North America is seen to have crossed over 49.3% in the year 2025. The key factors that boosted the North America viral vector manufacturing market include a rapid growth rate of the aerospace and energy industries in North America, which are seen to be the largest consumers of viral vector manufacturings. Furthermore, a robust base of companies in the region has further promoted innovation and growth in the viral vector manufacturing market. In addition, North America has a strong research and development infrastructure, with many universities and research institutions conducting cutting-edge research in materials science and engineering, further driving the viral vector manufacturing market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES VIRAL VECTOR MANUFACTURING MARKET ANALYSIS

The U.S. viral vector manufacturing market is growing fast as demand for gene therapies continues to increase along with advanced manufacturing technologies. In fact, as per a snapshot of global gene therapy trials, there were over 3,900 clinical trials across the world by March 2023, of which a majority was conducted in the United States, as per reports. The CHIPS and Science Act in 2022 gave authorization to USD 280 billion to advance U.S. scientific and technological research, some of which is aligning with advancements in biotechnology. Portfolio leaders, such as Thermo Fisher Scientific and Catalent, continue to add capacity in the United States to meet demand. Growth is driven by innovations in scalable production processes and federal incentives. This focus on quality and regulatory compliance helps strengthen U.S. leadership in viral vector manufacturing while exploiting export opportunities to improve its position globally in the biotech industry.

EUROPE VIRAL VECTOR MANUFACTURING MARKET ANALYSIS

The viral vector manufacturing market in Europe is growing as the investment in biotechnology and R&D funding is increasing. Horizon Europe, the European Union's leading research and innovation initiative, has designated EUR 11.5 billion (USD 12.6 billion) for the advancement of biotechnology and pharmaceutical research and development. InvestEU will also invest more than EUR 1 billion (USD 1.1 billion) in biotech and medicines-related investments, thus boosting innovation in vector production. BioNTech and Oxford Biomedica are some of the regional leaders in scalable manufacturing technologies. Strict regulatory frameworks by the EU guarantee the highest safety and quality standards for the production of cutting-edge therapies. Collaborative public-private partnerships and sustainable integration further boost Europe's position as a global hub for viral vector manufacturing, with strategic funding initiatives ensuring growth and technological advancement.

ASIA PACIFIC VIRAL VECTOR MANUFACTURING MARKET ANALYSIS

The Asia Pacific market for viral vector manufacturing is growing with a rapid speed as there has been an increasing investment in the field of biotechnology and governmental policies. As China's government invested heavily into the R&D in biotechnology, public R&D investment exceeded USD 3.8 billion from 2008 to 2020, as per reports, the commitment for advancements in gene therapy and viral vector technologies can be seen. The "Make in India" initiative by India and the regenerative medicine thrust by Japan are encouraging local manufacturing capabilities. Regional players such as WuXi AppTec and Samsung Biologics are exploiting partnerships to scale up and transfer technology. The growing clinical trials and need for cost-effective production solutions are making the region a major player in the global viral vector manufacturing market. Integration of new manufacturing technologies and supportive policies also fuels growth in the sector in Asia Pacific.

LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET ANALYSIS

The viral vector manufacturing market in Latin America is expected to expand in the upcoming years, fueled by higher investments in biotechnology and progress in gene therapy. GEMMABio has also recently announced a partnership with the health ministry in Brazil worth USD 100 million to introduce gene therapies for rare diseases into the country, taking a huge leap forward in accessing gene therapies across the region. Expanding its biotechnology sector, the industry will also grow at an estimated CAGR of 14.2% between 2024 and 2030 to help drive growing demand for manufacturing gene therapy in Brazil, as per an industry report. Strong biotechnology leadership from Brazil makes this strategic alliance position it strategically within Latin America's gene therapy and viral vector manufacturing market. Countries like Mexico and Argentina are also investing in local production capabilities and international collaborations, so Latin America will continue to strengthen its role in global biomanufacturing.

MIDDLE EAST AND AFRICA VIRAL VECTOR MANUFACTURING MARKET ANALYSIS

The viral vector manufacturing market in Middle East and Africa is growing by increasing healthcare spend and government interest in enhancing infrastructure of biotechnology. According to International Trade Administration (ITA), Saudi Arabia accounts for 60 percent of the Gulf Cooperation Council (GCC) countries' healthcare expenditure. In 2023, Saudi allocated USD 50.4 billion (16.96% of the budget) on healthcare and social development, emphasizing the importance and focus on biotechnology and the healthcare industries in the country. The Saudi Arabian Government is adopting healthcare privatization as part of Vision 2030, which includes significant investments into biotech and gene therapy manufacturing. This environment is making the region increasingly attractive to homegrown and foreign players alike and positions it well as a future hub for the manufacturing of viral vectors, as countries in the region seek to augment their self-sufficiency in advanced healthcare technologies.

COMPETITIVE LANDSCAPE:

The global viral vector manufacturing market is highly competitive, with leading companies focusing on technological advancements, expanding their production capabilities, and forming strategic partnerships to strengthen their market standing. Major companies dominate the market with extensive expertise and robust production capabilities. These firms invest heavily in R&D to enhance vector engineering, scalability, and manufacturing efficiency. Emerging players and contract development and manufacturing organizations (CDMOs) are also gaining traction by offering cost-effective solutions and specialized services. Partnerships between pharmaceutical companies, research institutes, and vector manufacturers are increasingly common, aimed at accelerating gene therapy development and commercialization. The competitive environment is also influenced by regional companies expanding their operations to address the increasing global demand for viral vectors.

The report provides a comprehensive analysis of the competitive landscape in the viral vector manufacturing market with detailed profiles of all major companies, including:

  • Aldevron LLC
  • Catalent, Inc
  • Charles River Laboratories International Inc.
  • Cytiva (Danaher Corporation)
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • Kaneka Corporation
  • Lonza
  • Merck KGaA
  • Oxford Biomedica PLC
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Viral Vector Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Adenoviral Vectors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adeno-associated Viral Vectors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Lentiviral Vectors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Retroviral Vectors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Genetic Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Vaccinology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Aldevron LLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Catalent, Inc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Charles River Laboratories International Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Cytiva (Danaher Corporation)
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche Ltd
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 FUJIFILM Diosynth Biotechnologies
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Genezen
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Kaneka Corporation
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Lonza
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Merck KGaA
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Oxford Biomedica PLC
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Viral Vector Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Viral Vector Manufacturing Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Viral Vector Manufacturing Market: Breakup by Disease (in %), 2025
  • Figure 6: Global: Viral Vector Manufacturing Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Viral Vector Manufacturing Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Viral Vector Manufacturing Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Viral Vector Manufacturing (Retroviral Vectors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Viral Vector Manufacturing (Retroviral Vectors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Viral Vector Manufacturing (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Viral Vector Manufacturing (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Viral Vector Manufacturing (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Viral Vector Manufacturing (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Viral Vector Manufacturing (Genetic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Viral Vector Manufacturing (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Viral Vector Manufacturing (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Viral Vector Manufacturing (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Viral Vector Manufacturing (Other Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Viral Vector Manufacturing (Other Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Viral Vector Manufacturing (Gene Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Viral Vector Manufacturing (Gene Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Viral Vector Manufacturing (Vaccinology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Viral Vector Manufacturing (Vaccinology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Viral Vector Manufacturing (Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Viral Vector Manufacturing (Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: North America: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: North America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: United States: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: United States: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Canada: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Canada: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Asia-Pacific: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Asia-Pacific: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: China: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: China: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Japan: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Japan: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: India: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: India: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: South Korea: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: South Korea: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Australia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Australia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Indonesia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Indonesia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Europe: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Europe: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Germany: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Germany: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: France: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: France: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: United Kingdom: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: United Kingdom: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Italy: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Italy: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Spain: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Spain: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Russia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Russia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Latin America: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Latin America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Brazil: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Brazil: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Mexico: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Mexico: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Middle East and Africa: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Middle East and Africa: Viral Vector Manufacturing Market: Breakup by Country (in %), 2025
  • Figure 83: Middle East and Africa: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Global: Viral Vector Manufacturing Industry: SWOT Analysis
  • Figure 85: Global: Viral Vector Manufacturing Industry: Value Chain Analysis
  • Figure 86: Global: Viral Vector Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Viral Vector Manufacturing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Viral Vector Manufacturing Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Viral Vector Manufacturing Market Forecast: Breakup by Disease (in Million USD), 2026-2034
  • Table 4: Global: Viral Vector Manufacturing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Viral Vector Manufacturing Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Viral Vector Manufacturing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Viral Vector Manufacturing Market: Competitive Structure
  • Table 8: Global: Viral Vector Manufacturing Market: Key Players